Farnum Rhonda's Form 4 filing
Theravance Biopharma, Inc.TBPH · filed Jul 16, 2025
- Accession no.
- 0001415889-25-019869
- Filed
- Jul 16, 2025
- Trade date
- Jul 14, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $113.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Farnum RhondaCIK 0001898490 | Officer (SVP, COMM & MEDICAL AFFAIRS) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 14, 2025 | Ordinary Shares | SSaleDisposed | −682 | $11.39F1 | −$7,767.98 | 336,236 | Direct | |
| Jul 14, 2025 | Ordinary Shares | SSaleDisposed | −5,318 | $11.39F2 | −$60,572.02 | 330,918 | Direct | |
| Jul 14, 2025 | Ordinary Shares | SSaleDisposed | −4,000 | $11.39F2 | −$45,560 | 326,918 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This transaction was executed in multiple trades at prices from $11.24 to $11.465 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F2
This transaction was executed in multiple trades at prices from $11.24 to $11.46 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 2 transactions in Table I.
Remarks
This transaction was executed in accordance with the reporting person's 10b5-1 plan dated 03/14/2024.